These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18037582)

  • 1. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
    D'Amico AV; Halabi S; Tempany C; Titelbaum D; Philips GK; Loffredo M; McMahon E; Sanford B; Vogelzang NJ; Small EJ;
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):9-15. PubMed ID: 18037582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
    D'Amico AV; Halabi S; Vollmer R; Loffredo M; McMahon E; Sanford B; Archer L; Vogelzang NJ; Small EJ; Kantoff PW;
    Urology; 2008 May; 71(5):933-7. PubMed ID: 18291508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo B; Kantoff PW
    J Clin Oncol; 2008 Jun; 26(18):2979-83. PubMed ID: 18565884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.
    Riaz N; Afaq A; Akin O; Pei X; Kollmeier MA; Cox B; Hricak H; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):707-11. PubMed ID: 22425220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.
    Nikitas J; Ong WL; Carrier N; Romero T; Millar J; Steinberg ML; Rettig MB; Boutros PC; Reiter R; Nickols NG; Valle L; McGuire SE; Spratt DE; Souhami L; Roy S; Martin JM; Joseph D; Nabid A; Kishan AU
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):826-831. PubMed ID: 38151191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
    D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
    JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer.
    Laverdière J; Nabid A; De Bedoya LD; Ebacher A; Fortin A; Wang CS; Harel F
    J Urol; 2004 Mar; 171(3):1137-40. PubMed ID: 14767287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
    Liauw SL; Pitroda SP; Eggener SE; Stadler WM; Pelizzari CA; Vannier MW; Oto A
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):378-84. PubMed ID: 22717242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
    J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.
    Fuchsjäger MH; Pucar D; Zelefsky MJ; Zhang Z; Mo Q; Ben-Porat LS; Shukla-Dave A; Wang L; Reuter VE; Hricak H
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):743-50. PubMed ID: 20133067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.